A new study published in Neural Regeneration Research reveals a novel approach to treating Parkinson’s disease (PD) using engineered probiotics. Researchers from Nanchang University have developed a modified strain of Lactococcus lactis that secretes glucagon-like peptide-1 (GLP-1), offering a novel way to target neuroinflammation and gut dysbiosis in PD.
The Study: Mechanisms and Results
Parkinson’s disease, the second most common neurodegenerative disorder, is characterised by the loss of dopaminergic neurons and the accumulation of toxic alpha-synuclein proteins. These processes are exacerbated by chronic inflammation and disruptions in the gut-brain axis.
The researchers engineered a strain of Lactococcus lactis (MG1363-pMG36e-GLP-1) to produce GLP-1, a peptide with known neuroprotective and anti-inflammatory properties. In experiments using transgenic mice with Parkinson’s-related mutations, the probiotic demonstrated the following effects:
1. Reduction in Neuroinflammation:
The probiotic inhibited the activation of microglia and astrocytes—immune cells in the brain that, when overactivated, contribute to neuronal damage.
2. Slows Down Loss of Dopaminergic Neurons:
Treated mice showed higher levels of tyrosine hydroxylase, a marker of healthy dopaminergic neurons, in the substantia nigra. This suggests a reduction in neuron loss, which is central to slowing PD progression.
3. Improved Gut Integrity:
The probiotic enhanced the expression of tight-junction proteins like ZO-1 and occludin, which are crucial for maintaining the gut barrier. This helps reduce systemic inflammation by preventing the leakage of harmful molecules such as lipopolysaccharides (LPS).
4. Reduction in Alpha-Synuclein Aggregates:
Levels of pathological alpha-synuclein and its phosphorylated forms were significantly lower in treated mice, pointing to the probiotic’s potential in addressing one of the core drivers of PD.
5. Enhanced Motor Function:
Behavioural tests showed significant improvements in motor abilities in probiotic-treated mice compared to untreated ones.
The Role of the Gut-Brain Axis
One of the most exciting aspects of this study is the focus on the gut-brain axis—a bidirectional communication pathway between the gastrointestinal tract and the central nervous system. Dysbiosis (an imbalance in gut microbiota) is increasingly recognised as a contributor to neurodegenerative diseases like Parkinson’s. The engineered probiotic not only rebalanced gut microbial diversity but also reduced systemic inflammatory markers, creating a healthier environment for the brain.
A Step Forward in Parkinson’s Research
Current Parkinson’s treatments, such as levodopa, focus on symptom management rather than addressing the underlying causes of the disease. The development of Lactococcus lactis MG1363-pMG36e-GLP-1 represents a shift toward targeting root causes, such as neuroinflammation and gut dysbiosis, offering hope for disease-modifying therapies.
Dr. Xin Fang, a lead researcher on the study, emphasised the significance of this approach:
“Our findings suggest that engineered probiotics can serve as both a delivery system and a therapeutic agent, addressing multiple pathways involved in Parkinson’s disease.”
Challenges and Future Directions
While the results are promising, several questions remain:
• Clinical Translation: More studies are needed to confirm safety and efficacy in humans.
• Delivery Optimization: Ensuring consistent probiotic colonisation in the human gut is a logistical challenge.
• Long-Term Effects: Understanding how prolonged use of engineered probiotics may influence gut and brain health will be critical.
Conclusion
This research not only paves the way for novel Parkinson’s treatments but also underscores the therapeutic potential of engineered probiotics for other neurodegenerative diseases. Alzheimer’s disease, multiple sclerosis, and even age-related cognitive decline could benefit from similar approaches targeting gut-brain communication and systemic inflammation.
The synergy between gut health and brain health is becoming increasingly clear, and this novel use of probiotics exemplifies how emerging technologies can be harnessed to address some of the most challenging diseases of our time.
Original Article: Yue, M., Chen, T., Chen, W., Wei, J., Liao, B., Zhang, J., … & Fang, X. The engineered probiotic strain Lactococcus lactis MG1363-pMG36e-GLP-1 regulates microglial polarization and gut dysbiosis in a transgenic mouse model of Parkinson’s disease. Neural Regeneration Research, 10-4103.https://doi.org/10.4103/NRR.NRR-D-24-00702
Discover more from Neurospan
Subscribe to get the latest posts sent to your email.
